NASDAQ · Biotechnology

MLYS (MLYS) Stock

$26.95 -0.96% NASDAQ: MLYS Healthcare

Valuation

MetricValue
Price$26.95
Market Cap$2.38B
P/E Ratio-15.07
P/B Ratio3.69
P/S Ratio0.00
EPS (TTM)$-2.29
52-Week High$47.65
52-Week Low$12.59
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-30.99%
ROA-21.27%
ROCE-26.43%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio44.07

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-19.0M$-31.0M$-85.0M$-192.0M$-171.0M
Net Profit$-19.0M$-30.0M$-72.0M$-178.0M$-155.0M
EPS$-3.89$-5.77$-1.99$-3.66$-2.29
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$11.0M$114.0M$252.0M$206.0M$662.0M
Total Liabilities$34.0M$167.0M$10.0M$15.0M$15.0M
Cash$11.0M$88.0M$49.0M$114.0M$173.0M
Borrowings$0$0$0$0$0

Latest News

A Mineralys Insider Banked a $557,000 Options Gain Before a December FDA Date Motley Fool · Jul 16, 2026 What to Know About This Mineralys Insider Sale Before a December FDA Date Motley Fool · Jul 16, 2026 A $500 Million Funding Deal Could Make Mineralys Therapeutics (MLYS) Stock A Multibagger Insider Monkey · Jul 3, 2026 Is Mineralys Therapeutics, Inc. (MLYS) Stock a Biotech Opportunity With Lorundrostat’s Expanding Cardiovascular Potential? Insider Monkey · Jul 2, 2026 Mineralys Therapeutics Insider Sold Shares Worth $2,696,322, According to a Recent SEC Filing MT Newswires · Jul 1, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-15.0M$-29.0M$-81.0M$-166.0M$-142.0M
Investing Cash Flow$0$-22.0M$-160.0M$115.0M$-390.0M
Financing Cash Flow$0$-2.0M$0$0$0
Net Cash Flow$9.0M$77.0M$-38.0M$65.0M$59.0M
Free Cash Flow$-15.0M$-29.0M$-81.0M$-166.0M$-142.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-115.73
EV / EBITDA-10.31
FCF Yield-7.03%
Quick Ratio44.33
Interest Coverage—
Return 1Y99.77%
Return 3Y78.22%
Return 5Y—

Ownership

Insiders Held0.56%
Institutions Held106.91%
Institutions Float Held107.51%
Institutional HolderSharesReport Date
Catalys Pacific, LLC7,903,8382026-03-31
RA Capital Management, L.P.7,692,7502026-03-31
Samsara BioCapital, LLC5,871,0182026-03-31
FMR, LLC4,861,1042026-03-31
Blackrock Inc.4,481,5822026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADPT $24.93 +5.64% -69.84 $3.99B 0.00%
AGIO $31.72 +0.38% -3.56 $1.89B 0.00%
APLSApellis Pharmaceuticals, Inc. $41.03 +0.00% 38.37 $5.25B 0.00%
BEAM $25.62 +2.19% -35.36 $2.64B 0.00%
CDTXCidara Therapeutics, Inc. $221.38 +0.00% -25.99 $5.61B 0.00%

About MLYS

MLYS stock trades at $26.95 with a market capitalization of $2.38B. The stock is valued at a price-to-earnings (P/E) ratio of -15.07, price-to-book of 3.69, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $12.59 and $47.65, and currently trades 43.4% below its 52-week high.

On profitability, MLYS generates a return on equity (ROE) of -30.99%, return on capital employed of -26.43%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides